Melanoma ECOG 1609

March 13, 2013

Location: The Hospital of Central Connecticut

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma.

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209
Reply STOP to cancel, HELP for help. Message and data rates may apply. See terms and privacy here.

Hartford HealthCare Offices

100 Pearl Street, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.

Interpretive Services

Community Health Needs Assessment
Financial Assistance
Price Transparency
Non-Discrimination
Patient Rights/Privacy
Website Terms/Conditions
Website Privacy Policy
Public Notices

Melanoma ECOG 1609

Connect With Us

Subscribe to Our Newsletters

Hartford HealthCare Offices